Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.6, 2008-06, pp. : 845-853

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incretin-Targeting Technologies for Type 2 Diabetes: Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

By Adis International Limited

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 7, 2006-07 ,pp. : 3-7

Adis International

Access to resources Recommend Favorite

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite

Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment

Current Drug Targets, Vol. 15, Iss. 6, 2014-06 ,pp. : 600-621

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

By Deacon Carolyn F Holst Jens J

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2047-2058

Informa Healthcare

Access to resources Recommend Favorite

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

By Ahrén Bo

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 4, 2008-12 ,pp. : 593-607

Informa Healthcare

Access to resources Recommend Favorite